Prior authorization applies to covered CPT codes when criteria are met

Prior authorization/coverage applies to CPT 91065 (breath hydrogen or methane test) and CPT 95012 (nitric oxide expired gas determination) only when the policy’s selection criteria are met (e.g., HBT after a 2‑week lactose‑free diet with persistent symptoms; FeNO for evaluation/monitoring of asthma in members ≥5 years).

• 91065 covered when HBT selection criteria met (after 2‑week lactose‑free diet with persistent symptoms).
• 95012 covered when FeNO selection criteria met (evaluation or monitoring of asthma in members aged ≥5 years).

If PA is requested for diagnostic/management uncertainty, document indication and rationale

When ordering FeNO or other exhaled tests to resolve diagnostic or management uncertainty, include the clinical indication and supporting rationale with prior‑authorization requests (for example: diagnostic uncertainty, suspected steroid responsiveness, or reason FeNO measurement is needed beyond routine care).

• State the indication (e.g., diagnostic uncertainty, suspected steroid responsiveness).
• Provide supporting clinical rationale and context for how the result will change management.

No explicit prior‑authorization requirement stated for FeNO in this policy excerpt

The policy excerpt does not establish payer‑level prior authorization rules for FeNO or other exhaled breath tests; local plan prior‑auth requirements should be confirmed separately.

• No explicit PA requirement for FeNO is specified in this document.
• Check the member’s benefit plan for any local prior‑authorization rules.

Policy excerpt does not specify payer PA for FeNO

This section does not state any payer‑level prior authorization requirements for FeNO testing; providers should not assume uniform PA rules across plans and must verify benefit‑specific authorization policies.

• Policy text does not specify payer PA triggers for FeNO.
• Confirm authorization requirements with the member’s plan.

Prior authorization likely for experimental or nonstandard exhaled tests

Because many exhaled breath condensate (EBC) methods and multi‑flow or other nonstandard exhaled techniques are described as experimental or research‑only, prior authorization or explicit documentation of medical necessity may be required when these nonstandard tests are ordered.

• EBC and many multi‑flow FeNO techniques are described as research/experimental and not established for routine clinical use.
• Payers may require PA or additional justification for investigational/nonstandard exhaled tests.

Document procedural protocol elements for breath tests in the record

Document the test protocol in the medical record for breath tests: for GEBT include overnight fast, baseline breath test, standardized 13C‑enriched protein test meal, and serial breath collections over four hours; for HBT document timed breath samples (every 15 minutes over a 2‑hour period) after the challenge carbohydrate.

• GEBT: overnight fast, baseline test, standardized 13C protein meal, serial collections over 4 hours.
• HBT: timed breath samples every 15 minutes during a 2‑hour testing period after ingestion of the challenge carbohydrate.

Provide validation evidence and external validation to justify coverage for investigational tests

When breath‑based diagnostic devices or test methods lack standardized reporting, external validation, or are investigational, provide independent validation evidence and methodologic details to justify coverage (e.g., validation studies, external cohorts, standardized cutpoints and analytic methods).

• Submit evidence of standardized reporting and external validation if available.
• Document that the device/method has been validated in appropriate populations or provide rationale for clinical use.

No PA requirements specified in these excerpts

This excerpt does not define any specific prior authorization requirements for exhaled breath tests; absence of specified PA in the policy does not preclude plan‑level authorization rules elsewhere—confirm with the payer.

• No PA requirements are specified in these excerpts.
• Verify plan‑specific authorization policies.

Consider standard symptom/spirometry‑based approaches before FeNO‑guided therapy

The document notes FeNO‑based adjustment of inhaled corticosteroids was not superior to symptom‑ or physician‑based adjustment in BASALT; consider standard symptom/spirometry‑based approaches before implementing FeNO‑guided algorithms.

• BASALT trial found no superiority of FeNO‑based adjustment versus physician or symptom‑based strategies for time to treatment failure.
• Consider established clinical monitoring before FeNO‑guided therapy.

No formal step‑therapy requirements specified for FeNO

No formal step‑therapy protocol is provided in this excerpt; FeNO may inform ICS initiation or titration but the policy does not require or specify step‑therapy sequencing or mandatory FeNO‑first steps.

• Policy states FeNO may guide ICS decisions but provides no formal step‑therapy protocol.
• No step therapy requirements are specified in the excerpt.

Do not substitute unvalidated EBT‑based adjustments for guideline‑directed monitoring

For asthma monitoring, do not substitute unvalidated exhaled breath temperature (EBT)‑based adjustments for established clinical assessments and guideline‑directed therapy without supporting validation.

• EBT measurement did not correlate with clinician treatment decisions or asthma control in a pediatric study; routine intermittent EBT monitoring to adjust ICS is not recommended.
• Use validated clinical assessments and guideline‑directed therapy for monitoring.

Required clinical documentation: show selection criteria are met for HBT and FeNO

Support HBT and FeNO claims with documentation that selection criteria are met: for HBT record that symptoms persisted after a 2‑week lactose‑free diet; for FeNO document patient age (≥5 years) and the asthma evaluation/monitoring indication.

• HBT: document a 2‑week trial of lactose avoidance with persistent symptoms prior to testing.
• FeNO: document age (≥5 years) and indication (evaluation or monitoring of asthma).

When FeNO is part of a multi‑component program, document FeNO’s specific role

When FeNO is used within a multi‑component asthma program, clearly document the specific role of FeNO versus other program components so outcomes attributable to FeNO can be evaluated (policy notes the contribution of FeNO could not be determined in multi‑component programs).

• Describe how FeNO results informed clinical decisions distinct from other program elements.
• Clarify FeNO frequency, thresholds used, and linkage to treatment changes.

Record FeNO measurement method and patient covariates when reporting results

Report FeNO measurement details and patient covariates used for interpretation (e.g., device/method — 50 ml/s online chemiluminescence per NHANES, age, sex, ethnicity, height, BMI, smoke exposure, allergic history) because population reference percentiles and prediction equations depend on these factors.

• Document testing method (flow rate, device type) and relevant covariates (age, sex, ethnicity, height, BMI, smoke exposure, hay fever).
• Reference population percentiles/prediction equations when applicable.

Report numeric FeNO value (ppb) and the cut‑points used for interpretation

Report FeNO values in parts per billion (ppb) and document the cut‑points or trial cutoffs used (examples cited include <25 ppb, 25–50 ppb, >50 ppb; trial cutoffs ranged 15–35 ppb) when results are used to support diagnostic or treatment decisions.

• Document the numeric FeNO value in ppb and the cut‑points used to interpret it.
• When used to support ICS initiation/titration, include whether patient was steroid‑naïve and the guideline comparator algorithm.

When using FeNO to guide ICS decisions, document value, context, comparator algorithm and treatment decisions

When FeNO is used to support initiation or titration of inhaled corticosteroids, document the FeNO value, clinical context (e.g., steroid‑naïve status), which guideline‑based comparator algorithm was used, and the treatment decision tied to the measurement.

• Include FeNO numeric value, patient steroid exposure status, comparator algorithm, and the specific treatment action taken.
• Tie the clinical decision directly to the measurement in the record.

Include test‑method details (device, ambient conditions, sampling/analysis) in reports

When reporting breath test results, document device type, ambient conditions (e.g., ambient temperature for EBT), sampling and analytical methods, and whether validated reference values or external validation cohorts were used.

• Document device model and analytic method.
• For EBT, record ambient temperature; for other tests, document sampling methods and any external validation used.

Denial trigger: billing codes for investigational/non‑covered exhaled tests may be denied

Use CPT codes only as specified by the policy: use CPT 83987 (EBC pH) or CPTs for tests labeled experimental/investigational only with caution — use of CPT codes not listed as covered (e.g., 83987) or codes for tests identified as experimental/investigational may trigger claim denial.

• Claims for EBC pH (CPT 83987) or other tests listed as investigational may be denied.
• Submit justification and evidence when billing for methods not listed as covered.

Denial risk: routine serial FeNO monitoring for management may be challenged

Claims that rely on routine serial FeNO monitoring for management may be challenged or denied because several randomized trials and meta-analyses did not show consistent improvement in clinical outcomes with routine FeNO‑based monitoring.

• Szefler et al. (2008) and BASALT (Calhoun et al., 2012) found no improvement in key outcomes with routine FeNO monitoring in some trials.
• Meta‑analyses show mixed results; routine serial FeNO monitoring is not consistently supported.

No explicit procedural or billing authorization rules stated in this excerpt — verify with payer

This document segment does not state explicit procedural or billing authorization requirements; however, clinical utility is described as limited or inconclusive in multiple contexts — verify local payer billing/authorization rules before ordering.

• No explicit PA or billing instructions are provided in these chunks.
• Verify plan‑specific authorization and billing policies.

No payer billing/authorization instructions in this excerpt — confirm with plan

No explicit payer authorization or billing instructions are present in these chunks; providers should confirm authorization and coding with the member’s plan since the policy focuses on clinical utility rather than plan‑specific PA triggers.

• Policy text does not supply payer PA triggers or billing instructions.
• Confirm authorization and coding with the plan prior to testing.

Nonstandardized EBC methods risk noncoverage

Methods and measurements for exhaled breath condensate are not standardized and lack validated clinical utility; ordering or billing for EBC methods without standardized methodology or validation may result in noncoverage.

• EBC collection and analysis lack standardization and reproducibility per ATS/ERS and reviews.
• Lack of validated clinical utility increases risk of noncoverage for EBC tests.

HBT protocol variability and cut‑off heterogeneity may affect coverage and interpretation

Hydrogen breath testing protocols and analyzers are heterogeneous and reported cut‑offs vary (suggested H2 thresholds 3–10 ppm to predict inadequate bowel prep); document local method and validation because variability could affect interpretation and lead to denials if the local method is not validated.

• HBT protocols vary; suggested hydrogen cut‑offs to distinguish adequate vs inadequate bowel prep ranged from 3–10 ppm.
• Document the protocol and analyzer used and any local validation data.

Validation and generalizability risk for unvalidated breath diagnostics

Tests and sensor‑array breath diagnostics without independent external validation, standardized reporting, or adequate sample sizes may have limited generalizability; provide validation data and standardized reporting when requesting coverage to mitigate denial risk.

• Electronic nose and breathomics studies often lack independent external validation and have small test‑set sample sizes limiting generalizability.
• Supply external validation and standardized accuracy reporting when available.

No explicit authorization/denial triggers in these chunks — verify plan rules and document medical necessity

The policy notes no explicit authorization or denial triggers in these chunks and clarifies that Clinical Policy Bulletins assist plan benefit administration; providers remain responsible for medical advice and treatment—confirm any required authorizations with the plan and ensure clinical documentation supports medical necessity.

• Clinical Policy Bulletins do not substitute for plan authorization processes.
• Providers should verify authorization and document medical necessity in the record.